Tags

Type your tag names separated by a space and hit enter

Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Circulation. 1993 Jun; 87(6 Suppl):VI71-7.Circ

Abstract

BACKGROUND

Two new questionnaires concerning the quality of life of patients with heart failure were used in a randomized, controlled trial to determine if the patients' perceptions of the effects of enalapril on their daily activities and sense of well-being were different from those of a group treated with hydralazine and isosorbide dinitrate.

METHODS AND RESULTS

The questionnaires were completed at baseline and at 3 months, 6 months, and subsequently every 6 months during follow-up, which averaged 2.5 years (range, 0.5-5.7 years). Data from the questionnaires were reliable as indicated by correlation coefficients between repeated baseline scores of 0.88 and 0.87. Both treatment groups showed a progressive deterioration in quality of life as measured by both questionnaires. The questionnaire scores of the two treatment groups were not significantly different at any follow-up visit. Furthermore, there were no differences between treatments among subgroups defined by baseline questionnaire scores, peak oxygen consumption, ejection fraction, previous vasodilator use, and plasma norepinephrine concentration.

CONCLUSIONS

Although several factors may limit the generalization of these results, the lack of a difference with regard to patients' quality of life is an important consideration for the evaluation of the relative therapeutic efficacy of these vasodilators.

Authors+Show Affiliations

Cardiovascular Division, University of Minnesota Medical School, Minneapolis 55455.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

8500243

Citation

Rector, T S., et al. "Evaluation By Patients With Heart Failure of the Effects of Enalapril Compared With Hydralazine Plus Isosorbide Dinitrate On Quality of Life. V-HeFT II. the V-HeFT VA Cooperative Studies Group." Circulation, vol. 87, no. 6 Suppl, 1993, pp. VI71-7.
Rector TS, Johnson G, Dunkman WB, et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 Suppl):VI71-7.
Rector, T. S., Johnson, G., Dunkman, W. B., Daniels, G., Farrell, L., Henrick, A., Smith, B., & Cohn, J. N. (1993). Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation, 87(6 Suppl), VI71-7.
Rector TS, et al. Evaluation By Patients With Heart Failure of the Effects of Enalapril Compared With Hydralazine Plus Isosorbide Dinitrate On Quality of Life. V-HeFT II. the V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 Suppl):VI71-7. PubMed PMID: 8500243.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. AU - Rector,T S, AU - Johnson,G, AU - Dunkman,W B, AU - Daniels,G, AU - Farrell,L, AU - Henrick,A, AU - Smith,B, AU - Cohn,J N, PY - 1993/6/1/pubmed PY - 1993/6/1/medline PY - 1993/6/1/entrez SP - VI71 EP - 7 JF - Circulation JO - Circulation VL - 87 IS - 6 Suppl N2 - BACKGROUND: Two new questionnaires concerning the quality of life of patients with heart failure were used in a randomized, controlled trial to determine if the patients' perceptions of the effects of enalapril on their daily activities and sense of well-being were different from those of a group treated with hydralazine and isosorbide dinitrate. METHODS AND RESULTS: The questionnaires were completed at baseline and at 3 months, 6 months, and subsequently every 6 months during follow-up, which averaged 2.5 years (range, 0.5-5.7 years). Data from the questionnaires were reliable as indicated by correlation coefficients between repeated baseline scores of 0.88 and 0.87. Both treatment groups showed a progressive deterioration in quality of life as measured by both questionnaires. The questionnaire scores of the two treatment groups were not significantly different at any follow-up visit. Furthermore, there were no differences between treatments among subgroups defined by baseline questionnaire scores, peak oxygen consumption, ejection fraction, previous vasodilator use, and plasma norepinephrine concentration. CONCLUSIONS: Although several factors may limit the generalization of these results, the lack of a difference with regard to patients' quality of life is an important consideration for the evaluation of the relative therapeutic efficacy of these vasodilators. SN - 0009-7322 UR - https://www.unboundmedicine.com/medline/citation/8500243/Evaluation_by_patients_with_heart_failure_of_the_effects_of_enalapril_compared_with_hydralazine_plus_isosorbide_dinitrate_on_quality_of_life__V_HeFT_II__The_V_HeFT_VA_Cooperative_Studies_Group_ L2 - https://medlineplus.gov/heartfailure.html DB - PRIME DP - Unbound Medicine ER -